C. Ballantyne

Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.

J. Danesh, R. Collins, A. Hofman, 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

n g l a d r n a l of m e d i c i n e Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

P. Libby, P. Pais, R. Glynn, 2017 .

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

S. Melquist, J. Knowles, P. Clifton, 2020 .

Clonal hematopoiesis and risk of chronic liver disease

Daniel Levy, B. Ebert, W. Wong, 2022, medRxiv.

TP53-mediated clonal hematopoiesis confers increased risk for incident peripheral artery disease

P. Libby, B. Ebert, S. Damrauer, 2021, medRxiv.

Efficacy and Safety of Bempedoic Acid in Patients With and Without Metabolic Syndrome: Pooled Analysis of Data From Four Phase 3 Clinical Trials

C. Ballantyne, M. Shapiro, P. Taub, 2023, medRxiv.

Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury

E. Boerwinkle, J. Coresh, B. Kestenbaum, 2023, medRxiv.

55 High-sensitivity cardiac troponin T and risk of hypertension

K. Matsushita, E. Selvin, C. Ballantyne, 2015, Circulation.

Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk

M. Eberle, D. Muzny, G. Metcalf, 2023, bioRxiv.

ARO-ANG3, an investigational RNAI therapeutic, decreases serum LDL-cholesterol, apolipoprotein B, and angiopoietin-like protein 3 in patients with homozygous familial hypercholesterolaemia

D. Gaudet, J. Hamilton, F. Raal, 2023, Atherosclerosis.